All Releases
 |
Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
Nov 23, 2009
|
10.7 KB |
| |
EMERYVILLE, Calif., Nov 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that its board of directors has declared an extraordinary dividend of $0.18 per share of common stock, which will be paid on December 9, 2009 to stockholders of record as of November 30, 2009. ...
|
|
Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and Dissolution
Oct 28, 2009
|
11.1 KB |
| |
EMERYVILLE, Calif., Oct 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that its stockholders have voted in favor of the company's dissolution pursuant to a plan of liquidation and dissolution at a special meeting of stockholders held on October 27, 2009. In connec...
|
|
Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
Oct 19, 2009
|
9.9 KB |
| |
EMERYVILLE, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today it has submitted written notice to the NASDAQ Stock Market LLC ("NASDAQ") that NTI intends to file a Form 25 with the Securities and Exchange Commission ("SEC") on or about October 28, 2009 to ...
|
|
Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
Sep 17, 2009
|
10.2 KB |
| |
EMERYVILLE, Calif., Sept 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq Stock Market indicating that the bid price of NTI's common stock has closed below $1.00 per share for 30 consecutive business ...
|
|
Neurobiological Technologies Announces Board Approval of Plan of Liquidation and Dissolution
Aug 31, 2009
|
15.3 KB |
| |
EMERYVILLE, Calif., Aug 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) (the "Company") today announced that its board of directors has determined, after consideration of potential strategic alternatives, that it is in the best interests of the Company and all its stockholders to...
|
|
Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center
Aug 12, 2009
|
10.2 KB |
| |
EMERYVILLE, Calif., Aug 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that it has entered into an agreement to terminate its license and cooperation agreement with Merz Pharmaceuticals GmbH (Merz) and Children's Medical Center Corporation (CMCC). Pursuant to th...
|
|
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
Jun 1, 2009
|
18.6 KB |
| |
EMERYVILLE, Calif., June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) has announced the results from its Phase 3 Clinical Program for XERECEPT(R) in patients with edema associated with brain tumors and fro...
|
|
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
May 8, 2009
|
14.4 KB |
| |
EMERYVILLE, Calif., May 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced financial results for the three-month and nine-month periods ended March 31, 2009.
Revenues for the third quarter of fiscal 2009 were $3.0 million compared to $3.7 million for the third quarte...
|
|
Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
May 1, 2009
|
10.2 KB |
| |
EMERYVILLE, Calif., May 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of Alzheimer's disease. Under an exclus...
|
|
Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
Mar 26, 2009
|
10.9 KB |
| |
EMERYVILLE, Calif., March 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced today that it has hired RBC Capital Markets as its exclusive financial advisor to assist in the evaluation of various options to enhance shareholder value, including a potential sale of the Compan...
|
|
Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
Feb 12, 2009
|
13.8 KB |
| |
EMERYVILLE, Calif., Feb 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced financial results for the three-month and six-month periods ended December 31, 2008.
Revenues for the second quarter of fiscal 2009 were $3.5 million compared to $3.7 million for the second q...
|
|
Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
Feb 4, 2009
|
11.1 KB |
| |
EMERYVILLE, Calif., Feb 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced the appointment of William A. Fletcher as the Company's Acting Chief Executive Officer. Mr. Fletcher has been a director of NTI since February 2007. With the Acting CEO appointment, the board...
|
|
Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
Feb 3, 2009
|
9.9 KB |
| |
EMERYVILLE, Calif., Feb 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a
quarterly royalty payment of approximately $1.5 million from Merz
Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of
Alzheimer's disease. Under an ...
|
|
Neurobiological Technologies Announces Suspension of Viprinex Development
Jan 13, 2009
|
11.6 KB |
| |
EMERYVILLE, Calif., Jan 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological
Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that, following a
detailed analysis of the recent interim results of the Viprinex(TM) clinical
trial, the company has decided not to develop Viprinex further for the
treatment of acute isc...
|
|
Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
Dec 17, 2008
|
10.6 KB |
| |
EMERYVILLE, Calif., Dec 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that an independent
Data Safety Monitoring Board (DSMB) has determined that the current clinical
trials of Viprinex(TM) for the treatment of acute ischemic stroke are unlikely
to show bene...
|
|
Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
Dec 16, 2008
|
14.1 KB |
| |
EMERYVILLE, Calif., Dec 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological
Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic
Pharmaceutical Holdings L.P. (Celtic) has provided an update on XERECEPT(R).
NTI sold the worldwide rights and assets related to XERECEPT to Celtic in
November 2005. NTI is ent...
|
|
Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
Nov 6, 2008
|
15.6 KB |
| |
EMERYVILLE, Calif., Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced its financial results for the quarter ended September 30, 2008, the first quarter of the company's fiscal year ending June 30, 2009. Revenue for the three months ended September 30, 2008 was $...
|
|
Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
Nov 5, 2008
|
10.7 KB |
| |
EMERYVILLE, Calif., Nov 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII), today announced that Paul E. Freiman, President and Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference November 10 to 12 at the New York Palace Hotel.
Mr. Freiman's pr...
|
|
Neurobiological Technologies Sets Date for First Quarter Financial Results
Nov 4, 2008
|
11.3 KB |
| |
EMERYVILLE, Calif., Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its first quarter 2009 financial results, for the quarter ended September 30, 2008, and host a conference call on November 6, 2008.
Hosting the call will be Paul E. Freima...
|
|
Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
Nov 3, 2008
|
10.5 KB |
| |
EMERYVILLE, Calif., Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $2.0 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's dise...
|
|
|
